SCHEMBL4035815

SCHEMBL4035815

Nc1n[nH]c2ccc(NC(=O)Cc3cccc(O)c3)cc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 7/20 0.55
JAK1 P23458 6/20 0.55
ULK1 O75385 4/20 0.55
AURKA O14965 4/20 0.54
TTK P33981 2/20 0.54
CDK2 P24941 3/20 0.50
NLRP3 Q96P20 3/20 0.48
PLK4 O00444 2/20 0.48
ROCK2 O75116 2/20 0.48
NTRK1 P04629 2/20 0.48
CDK1 P06493 2/20 0.48
PRKACA P17612 2/20 0.48
FLT1 P17948 2/20 0.48
RPS6KB1 P23443 2/20 0.48
MARK3 P27448 2/20 0.48
AKT1 P31749 2/20 0.48
FLT4 P35916 2/20 0.48
KDR P35968 2/20 0.48
FLT3 P36888 2/20 0.48
CSNK1D P48730 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL921534 0.99 JAK2 (0.54) JAK2JAK1ULK1AURKATTK
SCHEMBL12907285 0.87 JAK2 (0.67) JAK2JAK1ULK1AURKATTK
SCHEMBL12907278 0.87 JAK2 (0.55) JAK2JAK1ULK1AURKATTK
SCHEMBL4130093 0.84 AURKA (0.54) JAK2JAK1ULK1AURKAROCK2
SCHEMBL12907138 0.82 JAK2 (0.55) JAK2JAK1ULK1AURKATTK
SCHEMBL12907141 0.80 JAK2 (0.50) JAK2JAK1ULK1AURKATTK
SCHEMBL12907385 0.78 SGK1 (0.48) JAK2JAK1
SCHEMBL12907273 0.78 ROCK2 (0.62) JAK2AURKATTKCDK2PLK4
SCHEMBL12907292 0.78 TTK (0.53) JAK2JAK1ULK1TTKROCK2
SCHEMBL12907286 0.77 JAK2 (0.66) JAK2JAK1ULK1AURKATTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765788-B1 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES MERCK PATENT GMBH (DE) 2009-06-03 EP claimed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US claimed
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 US disclosed
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 US disclosed
EP-1765788-B1 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES MERCK PATENT GMBH (DE) 2009-06-03 EP disclosed
EP-1765788-B1 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES MERCK PATENT GMBH (DE) 2009-06-03 EP disclosed
US-7527655-B1 Reactive ink jet ink printing process SAWGRASS TECHNOLOGIES, INC. (US) 2009-05-05 US disclosed
US-20090021568-A1 Reactive Dye and Process of Printing Same XU MING 2009-01-22 US disclosed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US disclosed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US disclosed
EP-1765788-A2 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES MERCK PATENT GmbH (DE) 2007-03-28 EP disclosed
WO-2005123688-A2 3-AMINOINDAZOLES MERCK PATENT GMBH (DE) 2005-12-29 WO disclosed
US-6961076-B2 Reactive dye printing process SAWGRASS TECHNOLOGIES, INC. 2005-11-01 US disclosed
US-6840614-B2 Reactive dye printing process SAWGRASS TECHNOLOGIES, INC. 2005-01-11 US disclosed
US-20040219296-A1 Reactive dye printing process SAWGRASS TECHNOLOGIES, INC. 2004-11-04 US disclosed
US-20020101500-A1 Reactive dye printing process SAWGRASS TECHNOLOGIES, INC. 2002-08-01 US disclosed
EP-1194298-A1 USE OF REACTIVE DYE IN A THERMAL TRANSFER PRINTING PROCESS SAWGRASS SYSTEMS, INC. (US) 2002-04-10 EP disclosed
US-6348939-B1 Digital printable reactive dye and process SAWGRASS SYSTEMS, INC. 2002-02-19 US disclosed
US-20020012038-A1 DIGITAL PRINTABLE REACTIVE DYE AND PROCESS SAWGRASS TECHNOLOGIES, INC. 2002-01-31 US disclosed
WO-2000073084-A1 USE OF REACTIVE DYE IN A THERMAL TRANSFER PRINTING PROCESS SAWGRASS SYSTEMS, INC. (US) 2000-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232620-A1 3-Aminoindazoles SGK3, SGK1, SGK2 JAK2 562/4885JAK1 343/4885ULK1 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.